Introduction
Bartter syndrome, first described in 1962 [1] , is a group of closely related hereditary tubulopathies. All variants of the syndrome share several clinical characteristics including renal salt wasting, hypokalaemic metabolic alkalosis, hyperreninaemic hyperaldosteronism with normal blood pressure, and hyperplasia of the juxtaglomerular apparatus [2] [3] [4] . All forms of the syndrome are transmitted as autosomal recessive traits.
Three distinct clinical phenotypes have been distinguished, including antenatal Bartter syndrome, classic Bartter syndrome and Gitelman syndrome (Table 1) . Recently, however, phenotypic overlap has been noted, and additional variants of Bartter syndrome have been described (Table 1, Figure 1 ), thereby expanding the clinical spectrum of the syndrome and providing further insight into the pathophysiological mechanisms underlying this complex disorder. Over the past decade, the breakthrough in molecular biology and molecular genetics has produced the tools to investigate various forms of Bartter syndrome at the molecular level. As a result, exciting discoveries have been made and the underlying molecular defects in these variants have been defined. The molecular studies of Bartter syndrome have been important not only in clarifying the genetic basis of this tubulopathy, but also in providing new and important insight into the function of specific transport proteins and into the physiology of renal tubular reclamation of solutes.
Phenotypes
Traditionally, the disease has been classified into three distinct phenotypes (Table 1) . First, antenatal Bartter syndrome, also known as hyperprostaglandin E syndrome, is the most severe form of the disease. It is characterized by polyhydramnios, premature birth, life-threatening episodes of salt and water loss in the neonatal period, hypokalaemic alkalosis and failure to thrive, as well as hypercalciuria and early-onset nephrocalcinosis [4, 5] . Secondly, classic Bartter syndrome occurs in infancy or early childhood. It is characterized by marked salt wasting and hypokalaemia leading to polyuria, polydipsia, volume contraction, muscle weakness and growth retardation. Hypercalciuria and nephrocalcinosis may occur [2, 3] . Thirdly, Gitelman syndrome is characterized by a mild clinical presentation in older children or adults [6] . Patients may be asymptomatic and present with transient muscle weakness, abdominal pain, symptoms of neuromuscular irritability or unexplained hypokalaemia. Hypocalciuria and hypomagnesaemia are typical [4, 6] .
Recently, an additional variant of antenatal Bartter syndrome associated with sensorineural deafness, renal failure and typical appearance has been described (Table 1) [7] . Finally, in 2002, several patients with severe autosomal dominant hypocalcaemia associated with Bartter syndrome were reported (Table 1) [8, 9] . Aside from their deficient parathyroid hormone secretion and renal Ca 2þ and Mg 2þ wasting, these patients also have impaired tubular Cl -reabsorption, negative NaCl balance, hyperaldosteronism and marked hypokalaemia.
Pathogenesis
The pathogenesis of these pathophysiologically complex and heterogeneous disorders has been the subject of intensive research for the past four decades. Nevertheless, as late as 1995, the molecular basis of 
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Transepithelial Cl -transport in the TAL is a complex process that involves coordinated interplay between the luminal, bumetanide-sensitive Na þ -K þ -2Cl -cotransporter (NKCC2), the luminal, ATP-regulated, inwardly rectifying K þ channel (ROMK), the basolateral Cl -channel (ClC-Kb), as well as other cotransporters and channels ( Figure 1A ) [4, 11, 12] . Chloride is reabsorbed across the luminal membrane of the TAL cell by the activity of NKCC2. This cotransporter is driven by the low intracellular Na þ and Cl -concentrations generated by the Na þ -K þ -ATPase and ClC-Kb, respectively. In addition, ROMK enables functioning of NKCC2 by recycling K þ back to the renal tubular lumen. Chloride transport in the distal convoluted tubule occurs primarily via the luminal, thiazide-sensitive NaCl co-transporter (TSC) ( Figure  1B ) [11, 12] . Cl -exit to blood is mediated via basolateral Cl -channels.
Genetic variants
A series of genetic linkage and mutation detection studies by Lifton and co-workers [13] [14] [15] [16] Recent data, however, have suggested that the genotype-phenotype correlation is not so clear cut and that phenotypic overlap may occur. Konrad et al. [24] and Peters et al. [25] reported that mutations in CLCNKB can also cause phenotypes that overlap with either antenatal Bartter syndrome or Gitelman syndrome. Jeck et al. described three patients with three different CLCNKB mutations whose clinical course was characterized by gradual transition from classic Bartter syndrome to Gitelman syndrome phenotype [26] . A more recent study reported a large inbred Bedouin kindred from Northen Israel, which had 12 members who were affected with hypokalaemic tubulopathy [27] . The findings of the study demonstrated intrafamilial heterogeneity, namely the presence of Gitelman syndrome and classic Bartter syndrome phenotypes in affected family members, all of whom were homozygous for a R438H mutation in the CLCNKB locus.
These studies provide evidence that Gitelman syndrome, previously considered a genetically homogenous disorder, can be caused by mutation in a gene other than SLC12A3 (Table 1, Figure 1 ). The wide range of clinical phenotypes observed in patients with CLCNKB mutations has been attributed to alternative routes for basolateral Cl -exit such as the KCl co-transporter, the cystic fibrosis transmembrane conductance regulator (CFTR) or the voltage-gated Cl -channel, ClC5 [27] . It has been suggested that variation in expression and/or function in any one of these alternative transport systems may modify to variable degrees the derangement in ClC-Kb function, thereby influencing the disease phenotype [27] . Such a modifying effect could occur at the cellular/regulatory level, whereby one or more transport mechanisms are recruited to compensate for impaired ClC-Kb function or, alternatively, may be determined at the level of modifier genes.
A recent molecular finding, which has shed additional light on the molecular pathophysiology of Bartter syndrome, was the identification by Hildebrandt's and Jentsch's groups of barttin, a -subunit for ClC-Ka and ClC-Kb chloride channels (Table 1, Figure 1) [28, 29] . Barttin is a protein encoded by the BSND gene, mutations in which cause the variant of antenatal Bartter syndrome with sensorineural deafness and renal failure (Table 1) . Barttin co-localizes with the subunit of the Cl -channel in basolateral membranes of the renal tubule and inner ear epithelium [29] . It appears to mediate Cl -exit in the TAL (Figure 1 ) and Cl -recycling in K þ -secreting strial marginal cells in the inner ear.
Abnormalities in urinary mineral excretion
The loss-of-function mutations in the genes of TAL cell transporters in Bartter syndrome lead to the derangements in tubular handling of minerals observed in this syndrome [2, 4, 30] . Normally, the lumen to cell flux of Cl -via the NKCC2 cotransporter in the TAL and the exit of K þ from cell to lumen generate lumen-positive electrical potential, which, in turn, drives paracellular Ca 2þ and Mg reabsorption in the distal convoluted tubule induced by the high level of aldosterone, which is a characteristic of the syndrome [2, 12] .
Most recently, gain-of-function mutations of the gene for the calcium-sensing receptor (CaSR) causing autosomal dominant hypocalcaemia have been added to the expanding list of molecular defects resulting in Bartter syndrome (Table 1, Figure 1 ) [8, 9] . In the kidney, the CaSR is expressed mainly in the basolateral membrane of the cortical TAL (Figure 1 ) [31] . Activation of CaSR by high concentration of extracellular Ca 2þ or Mg 2þ or by gain-of-function mutation triggers intracellular signalling events, including production of arachidonic acid and inhibition of adenylate cyclase [31] . Both actions result in inhibition of ROMK activity, which, in turn, leads to reduction in the lumenpositive electrical potential. This effect of CaSR explains why patients with activating mutations in this receptor may present with both hypercalciuric hypocalcaemia and renal wasting of NaCl, resulting in Bartter-like syndrome. This association further underscores the strong link between tubular handling of minerals and renal salt homeostasis.
The exact mechanisms underlying the hypocalciuria and hypomagnesaemia in Gitelman syndrome remain to be elucidated. It has been hypothesized that the loss-of-function mutation in TSC causes hypocalciuria by the same mechanism as thiazides ( Figure 1 ) [4] . According to this hypothesis, impaired Na þ reabsorption across the luminal membrane of the distal convoluted tubular cell, coupled with continued exit of intracellular Cl -through basolateral Cl -channels, causes the cell to hyperpolarize. This, in turn, stimulates entry of Ca 2þ into the cell via luminal voltage-activated Ca 2þ channels [32] . In addition, the lowering of intracellular Na þ concentration facilitates Ca 2þ exit via basolateral Na þ /Ca 2þ exchanger. The reasons for renal Mg 2þ wasting and hypomagnesaemia typical of Gitelman syndrome are unknown [30] .
Conclusion
In the past decade, remarkable progress has been made in our understanding of the molecular pathogenesis of Bartter syndrome. Molecular genetics and molecular biology studies have led to the identification of important Bartter syndrome-causing mutations, have provided important insight into the defective molecular mechanisms underlying this complex syndrome and have greatly increased our understanding of the physiology of transport processes in the TAL and the DCT. Nevertheless, several issues remain unsettled and warrant additional research. Further studies are needed to define defects in other transporter genes that may underlie specific forms of the disease, to investigate the phenotypic variability observed in specific genotypic variants and to explore the role of modifier genes in this variability. The exact role of specific mutations in the pathogenesis of the electrolyte and mineral abnormalities in Bartter syndrome and Gitelman syndrome is a subject for future research that may include site-directed mutagenesis and functional studies in heterologous expression systems, as well as the use of transgenic animals. These studies may significantly improve our understanding of the mechanisms underlying renal salt homeostasis, urinary mineral excretion and blood pressure regulation in health and disease.
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